Golimumab pharmacokinetics in ulcerative colitis: A literature review

Therapeutic Advances in Gastroenterology

Volumn 10, Issue 1, 2017, Pages 89-100

  Harzallah, Ines ^a   Rigaill, Josselin ^a   Williet, Nicolas ^a   Paul, Stephane ^a   Roblin, Xavier ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

antibody to golimumab; golimumab; trough levels; UC

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; DRUG ANTIBODY; GOLIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

AGE; ALGORITHM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFECTION; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SIDE EFFECT; ULCERATIVE COLITIS;

EID: 85006386906     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X16676194     Document Type: Review

References (54)

1. Aalberse R., Stapel S., Schuurman J., Rispens T., (2009) Immunoglobulin G4: an odd antibody. Clin Exp Allergy 39: 469-477.
2. Adedokun O., Chan D., Padgett L., Xu Y., Hyams J., Turner D., et al. (2016a) Pharmacokinetics and exposure-response relationships of golimumab in pediatric patients with moderate to severe ulcerative colitis: results from a multicenter open label study. Gastroenterology 150: S590.
3. Adedokun O., Xu Z., Liao S., Marano C., Strauss R., Zhang H., et al. (2016b) Population pharmacokinetic modeling analysis of golimumab in adult patients with moderately to severely active ulcerative colitis. Gastroenterology 150: S408.
4. Adedokun O., Xu Z., Marano C., Strauss R., Zhang H., Davis H., et al. (2013) Effects of immunomodulators on the pharmacokinetics and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: results from phase 2/3 PURSUIT-SC induction and maintenance studies. United Eur Gastroenterol J 1: A80.
5. Adedokun O., Xu Z., Marano C., Strauss R., Zhang H., Johanns J., et al. (2014) Serum golimumab exposure and the incidence of selected safety events in patients with ulcerative colitis following treatment with golimumab: an exploratory analysis of the PURSUIT study data. Gastroenterology 146: S-588.
6. Adedokun O., Xu Z., Marano C., Strauss R., Zhang H., Johanns J., et al. (2016c) Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis pii: jjw133. 20 2016 [Epub ahead of print].
7. Ben-Horin S., Chowers Y., (2014) Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 11: 243-255.
8. Bingham C., Mendelsohn A., Kim L., Xu Z., Leu J., Han C., et al. (2015) Maintenance of clinical and radiographic benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: week-112 efficacy and safety results of the open-label long-term extension of a phase III, double-blind, randomized, placebo-controlled trial. Arthritis Care Res 67: 1627-1636.
9. Braun J., Deodhar A., Inman R., van der Heijde D., Mack M., Xu S., et al. (2012) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 71: 661-667.
10. Bressler B., Marshall J., Bernstein C., Bitton A., Jones J., Leontiadis G., et al. (2015) Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 148: 1035e3-1058e3.
11. Chen D., Chen Y., Hung W., Chen H., Hsieh C., Chen Y., et al. (2015) Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment. Ann Rheum Dis 74: 2261-2264.
12. Colombel J., Feagan B., Sandborn W., Van Assche G., Robinson A., (2012) Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 18: 349-358.
13. Colombel J., Reinisch W., Gibson P., Sandborn W., Feagan B., Xu S., et al. (2016) Delayed response to golimumab therapy: UC patient characteristics and long-term clinical outcome: post hoc analyses from the PURSUIT program. Gastroenterology 150: S778.
14. Danese S., (2013) IBD: Golimumab in ulcerative colitis: a 'ménage à trois' of drugs. Nat Rev Gastroenterol Hepatol 10: 511-512.
15. Detrez I., Dreesen E., van Stappen T., de Vries A., Brouwers E., van Assche G., et al. (2016) Variability in golimumab exposure: a 'real-life' observational study in active ulcerative colitis. J Crohns Colitis 10: 575-581.
16. DHaens G., Vermeire S., Baert F., Bossuyt P., Buisson A., Bouhnik Y., et al. (2016) Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn's disease: a prospective, randomised, multicentre trial (Tailorix). J Crohns Colitis 10: S24-S24.
17. Dulai P., Siegel C., Peyrin-Biroulet L., (2014) Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD. Gastroenterol Clin North Am 43: 441-456.
18. Frederiksen M., Ainsworth M., Brynskov J., Thomsen O., Bendtzen K., Steenholdt C., (2014) Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis 20: 1714-1721.
19. Garcês S., Demengeot J., Benito-Garcia E., (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72: 1947-1955.
20. Gibson P., Feagan B., Sandborn W., Marano C., Strauss R., Johanns J., et al. (2016) Maintenance of efficacy and continuing safety of golimumab for active ulcerative colitis: PURSUIT-SC maintenance study extension through 1 Year. Clin Transl Gastroenterol 7: e168.
21. Hyams J., Griffiths A., Veereman G., Turner D., Chan D., Adedokun O., et al. (2016) A multi-center open-label study assessing pharmacokinetics, efficacy, and safety of subcutaneous golimumab in pediatric patients with moderately-severely active ulcerative colitis. Gastroenterology 150: S132.
22. Jurado T., Plasencia C., Martin S., Navarro R., Bonilla G., Villalba A., et al. (2015) Comparison of golimumab levels detected by two different enzyme-linked immunosorbent assays: promonitor vs sanquin. Ann Rheum Dis 74: 471-471.
23. Kavanaugh A., McInnes I., Mease P., Krueger G., Gladman D., Gomez-Reino J., et al. (2009) Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60: 976-986.
24. Kawalec P., Pilc A., (2016) An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci 12: 1097-1109.
25. Kay J., Matteson E., Dasgupta B., Nash P., Durez P., Hall S., et al. (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 58: 964-975.
26. Keystone E., Genovese M., Klareskog L., Hsia E., Hall S., Miranda P., et al. (2009) Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68: 789-796.
27. Kneepkens E., Plasencia C., Krieckaert C., Pascual-Salcedo D., van der Kleij D., Nurmohamed M., et al. (2014) Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice. Ann Rheum Dis 73: 2217-2219.
28. Leu J., Mendelsohn A., Ford J., Davis H., Zhou H., Xu Z., (2014) Long-term pharmacokinetics of body surface area-adjusted doses of golimumab following repeated subcutaneous administrations in pediatric patients with polyarticular juvenile idiopathic arthritis. Arthritis Rheumatol 66: S55-S56.
29. Löwenberg M., de Boer N., Hoentjen F., (2014) Golimumab for the treatment of ulcerative colitis. Clin Exp Gastroenterol 7: 53-59.
30. Martín S., del Agua A., Torres N., Pascual-Salcedo D., Plasencia C., Ruiz-Argüello B., et al. (2015a) Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases. Clin Chem Lab Med CCLM 53: e297-e299.
31. Martín S., Ruiz del Agua A., Torres N., Pascual-Salcedo D., Plasencia C., Jurado T., et al. (2015b) Validation of a homogenous mobility shift assay (HSMA) for the measurement of golimumab (GLM) and antibodies-to-golimumab (ATG) in inflammatory bowel disease (IBD) patient serum. ACR/ARHP Annual Meeting. Abstract 2734. 29 2015 [Epub ahead of print].
32. Moore C., Corbett G., Moss A., (2016) Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease. J Crohns Colitis 10: 619-625.
33. Nanda K., Cheifetz A., Moss A., (2013) Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease. Am J Gastroenterol 108: 40-47.
34. O'Meara S., Nanda K., Moss A., (2014) Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 20: 1-6.
35. Ordás I., Feagan B., Sandborn W., (2012) Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 10: 1079-1087; quiz e85-e86.
36. Paul S., Moreau A., Del Tedesco E., Rinaudo M., Phelip J., Genin C., et al. (2014) Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm. Bowel Dis 20: 1288-1295.
37. Peyrin-Biroulet L., Bouhnik Y., Roblin X., Bonnaud G., Hagège H., Hébuterne X., (2016) French national consensus clinical guidelines for the management of ulcerative colitis. Dig Liver Dis 48: 726-733.
38. Reinisch W., Gibson P., Sandborn W., Feagan B., Marano C., Strauss R., et al. (2016) Safety, Efficacy, and pharmacokinetics of golimumab in patients with moderately to severely active ulcerative colitis: PURSUIT-SC Long term extension. Gastroenterology 150: S776-S777.
39. Roblin X., Rinaudo M., Del Tedesco E., Phelip J., Genin C., Peyrin-Biroulet L., et al. (2014b) Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 109: 1250-1256.
40. Roblin X., Rinaudo M., Sparrow M., Moreau A., Phelip J., Genin C., et al. (2014a) Pharmacokinetics in IBD: ready for prime time? Curr Drug Targets 15: 1049-1055.
41. Rosas J., Llinares-Tello F., Martín S., Senabre J., Salas E., Oliver S., et al. (2014) Evaluation of serum level of golimumab and antibodies anti-golimumab in patients with rheumatic diseases: results from a local registry. Ann Rheum Dis 73: Abstract 935.
42. Rutgeerts P., Feagan B., Marano C., Padgett L., Strauss R., Johanns J., et al. (2015) Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther 42: 504-514.
43. Rutgeerts P., Reinisch W., Feagan B., Sandborn W., Tarabar D., Hebzda Z., et al. (2014) How long should golimumab treatment be continued in patients with ulcerative colitis who do not respond to initial induction therapy? United Eur Gastroenterol J 2: A67.
44. Sandborn W., Feagan B., Marano C., Zhang H., Strauss R., Johanns J., et al. (2014a) PURSUIT-SC Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146: 85-95.
45. Sandborn W., Feagan B., Marano C., Zhang H., Strauss R., Johanns J., et al. (2014b) PURSUIT-M Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146: 96e1-109e1.
46. Sethu S., Govindappa K., Alhaidari M., Pirmohamed M., Park K., Sathish J., (2012) Immunogenicity to biologics: Mechanisms, prediction and reduction. Arch Immunol Ther Exp (Warsz.) 60: 331-344.
47. Shealy D., Cai A., Staquet K., Baker A., Lacy E., Johns L., et al. (2010) Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs 2: 428-439.
48. Steenholdt C., Bendtzen K., Brynskov J., Thomsen O., Ainsworth M., (2014a) Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 109: 1055-1064.
49. Steenholdt C., Brynskov J., Thomsen O., Munck L., Fallingborg J., Christensen L., et al. (2014b) Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 63: 919-927.
50. Vande Casteele N., Ferrante M., van Assche G., Ballet V., Compernolle G., van Steen K., et al. (2015) Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148: 1320e3-1329e3.
51. Vande Casteele N., Gils A., Singh S., Ohrmund L., Hauenstein S., Rutgeerts P., et al. (2013) Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 108: 962-971.
52. Xu Z., Lee H., Vu T., Hu C., Yan H., Baker D., et al. (2010) Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. Int J Clin Pharmacol Ther 48: 596-607.
53. Zhou H., Jang H., Fleischmann R., Bouman-Thio E., Xu Z., Marini J., et al. (2007) Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 47: 383-396.
54. Zhuang Y., Lyn S., Lv Y., Xu Z., Bouman-Thio E., Masterson T., et al. (2013) Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial. Clin Drug Investig 33: 795-800.